ATP synthase F0 subunit 6Genealiases: ATPase6 · MTATP6
Q-omics provides the consensus-scored MT-ATP6 profile across patient tissues and cancer cell-line models. MT-ATP6 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MT-ATP6 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, MT-ATP6 RNA expression shows 18,957 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, KIRC, and ACC as cancer lineages where MT-ATP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT-ATP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT-ATP6 survival associations across molecular data types. MT-ATP6 RNA expression shows survival associations in the most cancer types (22), followed by mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT-ATP6 RNA expression–survival associations across cancer types. High MT-ATP6 expression shows unfavorable associations in LUAD, SKCM and KIRC, but favorable associations in ACC, KIRP and LGG. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for MT-ATP6 RNA expression.
This table summarizes MT-ATP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for MT-ATP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT-ATP6 shows lower tumor expression in KIRC, KIRP, LIHC, BRCA and CHOL and higher tumor expression in KICH. The KIRC box plot shows higher MT-ATP6 RNA expression in normal versus tumor tissue (log2 FC = −0.924, t-test p < 0.001).
This table shows molecular features associated with MT-ATP6 in patient tissues and cancer cell lines. In patient samples, MT-ATP6 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MT-ATP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
